Publications by authors named "Michael Reusch"

Claim this Profile
P
POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery.
Alexander Zarbock, Christian Strauss, Maxime Laflamme, Andrej Myjavec, Johannes Böhm, Michael Reusch

Trials· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Pharmacokinetics and Safety of Therapeutic Alpha-1-Microglobulin in First-in-Human Kidney Transplantation: A Noncomparative Open-Label Multiple-Dose Phase 1b Study.
Johan E A Nordström, Lars M Wennberg, Greg Nowak, Tobias E Larsson, Sara J Thuresson, Michael Reusch

Transplant Direct· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.
Alexander Zarbock, Tobias E Larsson, Nicolas Noiseux, C David Mazer, Johannes Böhm, Michael Reusch

EClinicalMedicine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease.
Tomas Ganz, Francesco Locatelli, Mustafa Arici, Tadao Akizawa, Michael Reusch

J Clin Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca De Nicola, Michael Reusch

Adv Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.
Yasir J Sepah, Quan Dong Nguyen, Yusuke Yamaguchi, Tetsuro Otsuka, Yoshikatsu Majikawa, Michael Reusch

Kidney Int Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomised, open-label, active-controlled study (DOLOMITES).
Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch

Nephrol Dial Transplant· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Tadao Akizawa, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

Ther Apher Dial· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Jonathan Barratt, Wladyslaw Sulowicz, Michael Schömig, Ciro Esposito, Michael Reusch

Adv Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Botond Csiky, Michael Schömig, Ciro Esposito, Jonathan Barratt, Michael Reusch

Adv Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Tadao Akizawa, Yusuke Yamaguchi, Tetsuro Otsuka, Michael Reusch

Nephron· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
Evgeny Shutov, Władysław Sułowicz, Ciro Esposito, Avtandil Tataradze, Branislav Andric, Michael Reusch

Nephrol Dial Transplant· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch

Nephrol Dial Transplant· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
Tadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, Yusuke Yamaguchi, Michael Reusch

Kidney Int Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' Reply.
Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

J Am Soc Nephrol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors.
Werner Boecker, Michael Reusch, Volker Mielke, Ursula Reusch, Christian Hallermann

Am J Dermatopathol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Tadao Akizawa, Mai Ueno, Takanori Shiga, Michael Reusch

Ther Apher Dial· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' Reply.
Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

J Am Soc Nephrol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch

J Am Soc Nephrol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Tadao Akizawa, Tetsuro Otsuka, Michael Reusch, Mai Ueno

Ther Apher Dial· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Wolfram Sterry, Michael Reusch

J Dtsch Dermatol Ges· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Tadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, Michael Reusch, Toshihiro Misumi

Adv Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors.
Werner Boecker, Michael Reusch, Volker Mielke, Ursula Reusch, Thomas Loening

J Dermatol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0: A Validation Study.
Janine Topp, Matthias Augustin, Kathrin von Usslar, Ramona Gosau, Kristian Reich, Michael Reusch

Acta Derm Venereol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Praxis der Teledermatologie.
Matthias Augustin, Johannes Wimmer, Tilo Biedermann, Rolf Blaga, Christian Dierks, Michael Reusch

J Dtsch Dermatol Ges· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis